‘Fingerprinting’ Breast Cancer Cells

	Tweet

Researchers at the University of Arkansas are building a library of synthetically produced antibodies that can detect and rapidly validate proteins secreted by breast cancer cells. Their work will accelerate the process of developing a simple blood test for early detection of breast cancer.

“We want to implement a rapid screen that is sensitive – meaning highly accurate – non-invasive and inexpensive,” said Shannon Servoss, assistant professor of chemical engineering. “Such a test would be easy to use – as easy as a pregnancy test – and applicable to women of all ages, races and ethnicities. The ultimate goal, of course, is early detection of breast cancer.”

Researchers currently use specific protein binders called affinity reagents, which are molecules that interact with proteins, to recognize and validate proteins that indicate breast cancer. But this process is tedious and problematic because there are a limited number of affinity reagents available, and techniques to develop them are slow and expensive.

Servoss’s team seeks to overcome these obstacles by developing a collection of affitoids, which are synthetic, peptoid-based affinity reagents. A library of these affitoids, which are inexpensive and easy to make, will facilitate the development of techniques for protein validation.

The affitoids have other advantages. They can be designed to have desired properties, such as structural stability and specificity for a single protein. They also do not have to be limited to breast cancer detection. They could be designed to detect other complex diseases.

“This technique is superior to those currently available because affitoids specific for proteins secreted by breast cancer cells can be rapidly selected from a large collection, which isn’t too expensive to build,” Servoss said. “The selected affitoids will be used to determine a profile – a protein fingerprint – that indicates breast cancer. Of course, all of this is happening at the cell level, before the tumor is detectable.”

According to the Centers for Disease Control and Prevention, each year more than 40,000 women die due to breast cancer, and approximately 200,000 women are diagnosed with the disease. Early diagnosis leads to decreased mortality rates and allows for many more treatment options.

“It is imaginable that in this generation, a simple blood test could detect breast cancer at early stages and save thousands of lives,” Servoss said.

--
Source:  University of Arkansas, Fayetteville

RELATED STORIES:
U.S. black women have lower breast cancer survival   Linchpin Gene May Be Useful Target For Breast Cancer Therapies   Woman Beats Breast Cancer With Treatment In China   Childhood Cancer Survivors Show Inadequate Screening for Breast Cancer   Certain Breast Cancer Patients May Nix Node Surgery   DCIS patients who get invasive breast cancer have higher mortality   Understanding And Treating Triple-Negative Breast Cancer   European ancestry increases breast cancer risk among Latinas   Ultrasound Plus Mammography May Improve Breast Cancer Detection   Diagnostic and invasive procedures common in women with breast-conserving surgery   Estrogen receptor-alpha, breast cancer patients and tamoxifen response   Chemotherapy boosts breast cancer survival: study   Breast cancer patients prefer silicone over saline implants after mastectomy   Porter Adventist Hospital Breast Program Approved by NAPB   Scientists find new drug target in breast cancer   Few Women Rebuild Breast After Mastectomy   Alternating Mammography and MRI May Be Best for High-Risk Women   Breast cancer screening tied to overdiagnosis   High-risk women reluctant to take tamoxifen to prevent breast cancer   Walking Can Decrease Breast Cancer Recurrence 40 Percent   Regular use of COX-2 inhibitors reduces breast cancer risk   Erbitux may help fight breast cancer, claims study

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]